Folic acid prevents the progesterone-promoted proliferation and migration in breast cancer cell lines
- 88 Downloads
We previously demonstrated that progesterone (P4) interacted with folic acid (FA) and abolished the FA-reduced endothelial cell proliferation and migration. These findings led us to investigate whether FA can interfere with the P4-promoted breast cancer cell proliferation and migration.
We conducted MTT and wound healing assay to evaluate cell proliferation and migration, respectively. Western blot analysis and immunoprecipitation were performed to examine the protein expression and protein–protein interaction, respectively.
We demonstrated that P4 promoted proliferation and migration of breast cancer cell lines (T47D, MCF-7, BT474, and BT483). However, co-treatment with P4 and FA together abolished these promotion effects. Treatment with P4 alone increased the formation of PR-cSrc complex and the phosphorylation of cSrc at tyrosine 416 (Tyr416). However, co-treatment with P4 and FA together increased the formations of cSrc-p140Cap, cSrc-Csk, and cSrc-p-Csk complex, and the phosphorylation of cSrc at tyrosine 527 (Tyr527). Co-treatment with P4 and FA together also abolished the activation of cSrc-mediated signaling pathways involved in the P4-promoted breast cancer cell proliferation and migration.
Co-treatment with FA and P4 together abolished the P4-promoted breast cancer cell proliferation and migration through decreasing the formation of PR-cSrc complex and increasing the formations of cSrc-p140Cap and cSrc-Csk complex, subsequently activating Csk, which in turn suppressed the phosphorylation of cSrc at Tyr416 and increased the phosphorylation of cSrc at Tyr527, hence inactivating the cSrc-mediated signaling pathways. The findings from this study might provide a new strategy for preventing the P4-promoted breast cancer progress.
KeywordsCsk cSrc p140Cap p-cSrcY416 p-cSrcY527
This work was supported by the research grant from the Ministry of Science and Technology, R.O.C. (MOST 107-2320-B-038 -051 -MY3).
Compliance with ethical standards
Conflict of interests
The authors have not conflict of interest.
- 2.Dao TL (1981) The role of ovarian steroid hormones in mammary carcinogenesis. In: Pike MC, Siiteri PK, Welsch CW (eds) Hormones and breast cancer. Banbury report no. 8. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 281–289Google Scholar
- 3.Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):7–35. https://doi.org/10.1093/oxfordjournals.epirev.a036102 CrossRefGoogle Scholar
- 4.Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616. https://doi.org/10.1093/jnci/94.8.606 CrossRefGoogle Scholar
- 6.Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712. https://doi.org/10.1210/me.2006-0337 CrossRefGoogle Scholar
- 8.Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP (2007) The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21(2):359–375. https://doi.org/10.1210/me.2006-0337 CrossRefGoogle Scholar
- 10.Saitoh M, Ohmichi M, Takahashi K, Kawagoe J, Ohta T, Doshida M, Takahashi T, Igarashi H, Mori-Abe A, Du B, Tsutsumi S, Kurachi H (2005) Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology 146(11):4917–4925. https://doi.org/10.1210/en.2004-1535 CrossRefGoogle Scholar
- 11.Fu XD, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, Gadducci A, Genazzani AR, Simoncini T (2008) Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One 3(7):e2790. https://doi.org/10.1371/journal.pone.0002790 CrossRefGoogle Scholar
- 16.Hou TC, Lin JJ, Wen HC, Chen LC, Hsu SP, Lee WS (2013) Folic acid inhibits endothelial cell migration through inhibiting the RhoA activity mediated by activating the folic acid receptor/c-SRC/p190RhoGAP-signaling pathway. Biochem Pharmacol 85(3):376–384. https://doi.org/10.1016/j.bcp.2012.11.011 CrossRefGoogle Scholar
- 26.Di Stefano P, Damiano L, Cabodi S, Aramu S, Tordella L, Parduroux A, Pica R, Cavallo F, Forni G, Silengo L, Tarone G, Turco E, Defilippi P (2007) p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. EMBO J 26(12):2843–2855. https://doi.org/10.1038/sj.emboj.7601724 CrossRefGoogle Scholar
- 33.Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y (1993) p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J 12(1):307–314. https://doi.org/10.1002/j.1460-2075.1993.tb05658.x CrossRefGoogle Scholar
- 39.Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP (2001) Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8(2):269–280. https://doi.org/10.1016/S1097-2765(01)00304-5 CrossRefGoogle Scholar
- 40.Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9(5):1603–1614. https://doi.org/10.1002/j.1460-2075.1990.tb08280.x CrossRefGoogle Scholar